Discussions will include: Targeted Alpha Emitters with Focus on Actinium-225 Radiotherapies; Novel Radiopharmaceuticals: Standards Development, Product Quality Considerations, Supply and Demand; Clinical Considerations for Development of Novel Radiopharmaceuticals; User and Industry Perspective.